LH FINANCIAL STATEMENTS

Laboratory Corporation of America Holdings — balance sheet, income statement and cash flow trends

LHLaboratory Corporation of America Holdings

🇺🇸 USA · US · Healthcare · Diagnostics & Research

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue14.1 B $+7.3%

Gross Profit3.9 B $+6.9%

Operating Income1.6 B $+43.0%

EBITDA2.1 B $+13.9%

Net Income941.5 M $+28.8%

Peer Comparison· Diagnostics & Research

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
LH	7.3%	27.8%	14.6%	6.7%
ERF	5.0%	12.3%	19.9%	6.5%
SHL	11.4%	29.6%	17.3%	5.2%
Industry median	9.1%	53.0%	18.8%	6.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
LH	7.3%	27.8%	14.6%	6.7%
DGX	11.0%	33.2%	18.8%	9.1%
GH	39.6%	64.9%	-36.2%	-40.1%
MTD	6.8%	57.8%	30.6%	21.4%
ILMN	1.2%	67.7%	32.1%	19.4%
WAT	26.4%	55.0%	24.5%	11.9%
Industry median	9.1%	53.0%	18.8%	6.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity8.7 B $46%
Current Liabilities2.6 B $14%
Long-term Liabilities7.7 B $40%

Key Figures

YoY change

Total Assets19.1 B $+8.4%

Total Liabilities10.3 B $+11.4%

Total Equity8.7 B $+5.1%

Cash & ST Investments981.1 M $+165.6%

Total Debt7.2 B $+11.1%

Net Debt6.3 B $+1.8%

Peer Comparison· Diagnostics & Research

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
LH	1.73	83.0%	3.03	45.7%
ERF	1.09	153.3%	3.20	32.3%
SHL	1.01	85.8%	3.78	50.3%
Industry median	1.87	49.3%	1.92	50.1%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
LH	1.73	83.0%	3.03	45.7%
DGX	1.18	94.8%	3.10	44.2%
GH	4.68	-941.4%	-1.54	-9.5%
MTD	1.20	-5,321.1%	1.73	-1.1%
ILMN	1.75	95.1%	0.99	40.8%
WAT	1.79	36.4%	5.53	62.3%
Industry median	1.87	49.3%	1.92	50.1%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow1.8 B $+11.0%

Capital Expenditures429.5 M $-10.9%

Free Cash Flow1.4 B $+20.1%

Dividends Paid-240.3 M $-199.1%

Peer Comparison· Diagnostics & Research

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
LH	12.8%	9.8%	3.0%	192.6%
ERF	17.7%	7.3%	10.4%	272.6%
SHL	13.1%	8.3%	4.7%	251.9%
Industry median	16.3%	9.7%	4.5%	110.1%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
LH	12.8%	9.8%	3.0%	192.6%
DGX	16.4%	11.8%	4.6%	180.7%
GH	-16.2%	-20.8%	4.6%	40.5%
MTD	22.0%	19.4%	2.6%	103.0%
ILMN	25.7%	22.5%	3.2%	132.2%
WAT	10.3%	7.0%	3.3%	86.8%
Industry median	16.3%	9.7%	4.5%	110.1%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on LH

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.